Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

CRISPR Therapeutics AG - Common Shares (NQ:CRSP)

53.82 +4.89 (+9.99%)
Streaming Delayed Price Updated: 11:19 AM EST, Feb 13, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about CRISPR Therapeutics AG - Common Shares

< Previous 1 2
...
23 24 25 26 27 28 29 30 31
...
35 36 Next >
News headline image
Cathie Wood Gets Elon Musk's Attention Over Gene-Editing Therapy Potential: 'Investors Chased The Dream Then. Now, They're Running Away' ↗
Cathie Wood of ARK Investment Management believes U.S. equity markets are the polar opposite of what they were in the 90s when investors chased their dreams. 
Via Benzinga
News headline image
Cathie Wood Is Buying These Top Growth Stocks -- and Both Could Make You Rich Over Time ↗
Wood is bargain hunting now. And these buys may pay off big in the long run. 
Via The Motley Fool
News headline image
3 Growth Stocks That Could Skyrocket 50% or More In 2023, According to Wall Street ↗
These stocks fell significantly in 2022. But analysts expect that huge rebounds could be on the way in the new year. 
Via The Motley Fool
News headline image
1 Cathie Wood Stock to Buy While It's Affordable, and 1 to Avoid (for Now) ↗
Both stocks have fallen brutally this year, but only one has a chance to recover soon. 
Via The Motley Fool
News headline image
2 Cathie Wood Stocks to Buy and Hold Through 2023 and Beyond ↗
These two biotechs are flying high right now. 
Via The Motley Fool
News headline image
5 Unstoppable Trends to Invest $5,000 in for 2023 ↗
These trends won't fade away, and some of the companies that are positioned to ride them should be big winners. 
Via The Motley Fool
News headline image
Could CRISPR Therapeutics Help You Become a Millionaire? ↗
The gene-editing stock still has plenty of promise. 
Via The Motley Fool
News headline image
Is Vertex Pharmaceuticals a Buy? ↗
There's more growth ahead for this biotech giant. 
Via The Motley Fool
News headline image
After Doubling in the Past 6 Months, Is This Stock a Buy? ↗
This company has had a solid year, but there is still plenty of work ahead. 
Via The Motley Fool
News headline image
Crispr Stock In 2023: Will Down-In-The-Dumps Shares Sparkle Again In 2023? ↗
Crispr and Vertex are working toward the first submissions for a CRISPR-based product. 
Via Investor's Business Daily
News headline image
2 No-Brainer Biotech Stocks to Buy Right Now ↗
Vertex Therapeutics and Amgen have the building blocks for long-term success. 
Via The Motley Fool
News headline image
3 Cathie Wood Stocks That Could Make Big Comebacks in 2023 ↗
These businesses aren't in as much trouble as their stock returns suggest that they are. 
Via The Motley Fool
News headline image
3 Growth Stocks That Are Screaming Buys in December ↗
Don't let these companies pass you by the next time you go stock shopping. 
Via The Motley Fool
News headline image
Better Bear Market Buy: Vertex Pharmaceuticals vs. Biogen Stock ↗
Both stocks are heading for double-digit gains this year. 
Via The Motley Fool
News headline image
3 Beaten-Down Stocks That Could Explode Higher in 2023 ↗
These stocks could have significant upside opportunities ahead. 
Via The Motley Fool
News headline image
7 Stocks to Add to Your 10x Watchlist ↗
It’s always a good time to look for stocks with exceptional growth potential. Here are seven 10x stocks for your watchlist. 
Via InvestorPlace
News headline image
3 Growth Stocks With More Potential Than Any Cryptocurrency ↗
If the crypto meltdown has you discouraged, don't give up on stocks. 
Via The Motley Fool
News headline image
3 Red-Hot Stocks That Could Continue to Beat the Market ↗
The success these stocks achieved in 2022 could be just the beginning. 
Via The Motley Fool
News headline image
Vertex and CRISPR Therapeutics to Present at the American Society of Hematology (ASH) Annual Meeting and Exposition
From Vertex Pharmaceuticals Incorporated
Via Business Wire
News headline image
Want to Be Ready For a New Bull Market? Do These 3 Things Soon ↗
It's easier to make money in bull markets when you've done the prep work beforehand. 
Via The Motley Fool
News headline image
2 Growth Stocks That Could Help Set You Up for Life ↗
Many growth stocks are down, but they're not all out. 
Via The Motley Fool
News headline image
5 Best Bargain Stocks to Buy Before 2023 ↗
It's time to hit the best sale in town, and that involves many top stocks. 
Via The Motley Fool
News headline image
3 Revolutionary Stocks I'd Buy Right Now Without Hesitation ↗
The three companies are changing the pharmaceutical industry. 
Via The Motley Fool
News headline image
Is CRISPR Therapeutics a Buy? ↗
A strong cash position could offset some of the near-term risks that come with owning the biotech. 
Via The Motley Fool
News headline image
Precigen's Overnight Cell Manufacturing Technology Could Offer Advanced AML Patients The Option Of Promising CAR-T Therapy ↗
-Clinical Data Due Next Week at ASH- 
Via Benzinga
News headline image
2 Unstoppable Growth Stocks to Buy in 2022 and Beyond ↗
These biotech players beat the bear market this year. 
Via The Motley Fool
News headline image
3 Fierce Stocks That Are Screaming Buys in December ↗
Here are three winners in the making. 
Via The Motley Fool
News headline image
Is It Too Late to Buy Vertex Pharmaceuticals Stock? ↗
The company has already made plenty of investors happy. 
Via The Motley Fool
News headline image
Bear Market Bargain Hunting: 3 Top Stocks to Buy Before 2023 ↗
These top players are ripe for recovery -- and long-term growth. 
Via The Motley Fool
News headline image
3 Growth Stocks That Are Too Cheap to Ignore ↗
Overlooking these stocks in the current market could be a mistake. 
Via The Motley Fool
< Previous 1 2
...
23 24 25 26 27 28 29 30 31
...
35 36 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.